Engineering Single-Atomic Iron-Catalyst-Integrated 3D-Printed Bioscaffolds for Osteosarcoma Destruction with Antibacterial and Bone Defect Regeneration Bioactivity
- PMID: 34146359
- DOI: 10.1002/adma.202100150
Engineering Single-Atomic Iron-Catalyst-Integrated 3D-Printed Bioscaffolds for Osteosarcoma Destruction with Antibacterial and Bone Defect Regeneration Bioactivity
Abstract
Effective antitumor therapeutics with distinctive bactericidal and osteogenic properties are in high demand for comprehensive osteosarcoma treatment. Here, a "scaffold engineering" strategy that integrates highly active single-atomic iron catalysts (FeSAC) into a 3D printed bioactive glass (BG) scaffold is reported. Based on the atomically dispersed iron species within the catalysts, the engineered FeSAC displays prominent Fenton catalytic activity to generate toxic hydroxyl radicals (•OH) in response to the microenvironment specific to osteosarcoma. In addition, the constructed FeSAC-BG scaffold can serve as a sophisticated biomaterial platform for efficient osteosarcoma ablation, with concomitant bacterial sterilization via localized hyperthermia-reinforced nanocatalytic therapeutics. The destruction of the osteosarcoma, as well as the bacterial foci, can be achieved, further preventing susceptible chronic osteomyelitis during osteogenesis. In particular, the engineered FeSAC-BG scaffold is identified with advances in accelerated osteoconduction and osteoinduction, ultimately contributing to the sophisticated therapeutics and management of osteosarcoma. This work broadens the biomedical potential of single-atom catalysts and offers a comprehensive clinically feasible strategy for overall osteosarcoma therapeutics, bacterial inhibition, and tissue regeneration.
Keywords: bioscaffolds; nanocatalytic therapy; osteogenesis; osteosarcoma; single-atom catalysts.
© 2021 Wiley-VCH GmbH.
References
-
- M. Kansara, M. W. Teng, M. J. Smyth, D. M. Thomas, Nat. Rev. Cancer 2014, 14, 722.
-
- Y. Chen, M. A. Di Grappa, S. D. Molyneux, T. D. McKee, P. Waterhouse, J. M. Penninger, R. Khokha, Sci. Transl. Med. 2015, 7, 317ra197.
-
- R. J. Grimer, Lancet Oncol. 2005, 6, 85.
-
- P. A. Meyers, J. H. Healey, A. J. Chou, L. H. Wexler, P. R. Merola, C. D. Morris, M. P. Laquaglia, M. G. Kellick, S. J. Abramson, R. Gorlick, Cancer 2011, 117, 1736.
-
- B. Chen, H. Xiang, S. Pan, L. Yu, T. Xu, Y. Chen, Adv. Funct. Mater. 2020, 30, 2002621.
MeSH terms
Substances
Grants and funding
- 2016YFA0203700/National Key Research and Development Program of China
- GJHZ2072/UNSW-CAS Collaborative Research Seed Program
- 82001944/National Natural Science Foundation of China
- 81725008/National Natural Science Foundation of China
- 81601502/National Natural Science Foundation of China
- 81671695/National Natural Science Foundation of China
- 81927801/National Natural Science Foundation of China
- 2019M661634/China Postdoctoral Science Foundation
- 2019TQ0231/China Postdoctoral Science Foundation
- 19DZ2251100/Science and Technology Commission of Shanghai Municipality
- 2019LJ21/Shanghai Municipal Health and Family Planning Commission
- SHSLCZDZK 03502/Shanghai Municipal Health and Family Planning Commission
LinkOut - more resources
Full Text Sources
Medical